Showing 1 - 4 results of 4 for search '(((("i values decrease") OR ("c largest decrease"))) OR ("c levels increased"))*', query time: 0.57s Refine Results
  1. 1

    Data Sheet 1_The effects of kratom (Mitragyna speciosa) on metabolic syndrome-related parameters: a systematic review and meta-analysis.pdf by Ajaree Rayanakorn (8399466)

    Published 2025
    “…The meta-analysis involving 1,458 adults observed significantly lower levels of serum low-density lipoprotein cholesterol (LDL-c) (MD -0.25-0.21 mmol/L; 95% CI: −0.39, −0.02), triglyceride (MD -0.17 mmol/L; 95% CI: −0.25, −0.09), while high-density lipoprotein cholesterol (HDL-c) levels increased (MD 0.07 mmol/L; 95% CI: 0.03, 0.11). …”
  2. 2

    Data Sheet 1_Effects of drospirenone and ethinylestradiol tablets (II) combined with metformin on the composition of gut microbiota in polycystic ovary syndrome with insulin resist... by Yanglu Liu (22417861)

    Published 2025
    “…After treatment, CHO levels decreased in PCOS-NIR group (P < 0.05); FINS, LDL-C and HOMA-IR decreased and HDL-C levels increased in PCOS-IR group (P < 0.05). 2. Characteristics of gut microbiota: before treatment, there was no significant difference in α and β diversity between PCOS-NIR group and PCOS-IR group. …”
  3. 3

    Image 1_Cerebral small vessel disease as a possibly immune-related adverse event of immunotherapy in lung cancer patients: a retrospective study.tif by Na Wu (240778)

    Published 2025
    “…TSH levels increased from 4.12 ± 0.46 pmol/L to 4.78 ± 1.13 pmol/L, cysteine C levels increased from 1.01 ± 0.98 mg/L to 1.29 ± 0.86 mg/L, PLR increased from 164.93 ± 27.86 to 171.27 ± 32.29 and SII rose from 774.28 ± 53.57 to 790.65 ± 68.34. …”
  4. 4

    Figure 2 from mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of <i>PIK3CA</i>-Altered Tumors by Constance A. Sobsey (19373550)

    Published 2025
    “…Node size increases as the <i>P</i>-value decreases. <b>B,</b> Top 20 canonical pathways that are significantly differentially activated between clinical benefit (CB) and no clinical benefit (NCB) groups, based on assessment with Fisher’s exact test in Qiagen IPA. …”